EP 3555115 A4 20200805 - NOVEL COMPOUNDS AS ANTI-MYCOBACTERIALS
Title (en)
NOVEL COMPOUNDS AS ANTI-MYCOBACTERIALS
Title (de)
NEUARTIGE VERBINDUNGEN ALS ANTI-MYCOBAKTERIEN
Title (fr)
NOUVEAUX COMPOSÉS EN TANT QU'AGENTS ANTI-MYCOBACTÉRIENS
Publication
Application
Priority
- AU 2016905229 A 20161216
- AU 2017051394 W 20171215
Abstract (en)
[origin: WO2018107236A1] The present disclosure relates to antibacterial compounds. In particular, the compounds are for inhibiting the growth of bacteria, particularly Mycobacterium tuberculosis (Mtb), and/or targeting bacteria having phospho-MurNAc-pentapeptide translocase. The present disclosure also relates to compositions containing these compounds and methods of the use of these compounds and compositions.
IPC 8 full level
C07K 5/02 (2006.01); A61K 38/00 (2006.01); A61K 38/04 (2006.01); A61K 38/07 (2006.01); A61P 11/00 (2006.01); A61P 31/04 (2006.01); A61P 31/06 (2006.01); A61P 31/08 (2006.01); C07K 5/037 (2006.01)
CPC (source: EP)
A61P 11/00 (2017.12); A61P 31/04 (2017.12); A61P 31/06 (2017.12); A61P 31/08 (2017.12); C07K 5/0215 (2013.01); C07K 5/0217 (2013.01); A61K 38/00 (2013.01)
Citation (search report)
- [Y] CN 105755076 A 20160713 - INST OF MEDICINAL BIOTECHNOLOGY CHINESE ACAD OF MEDICAL SCIENCES
- [Y] YUANYUAN SHI ET AL: "Improving the N-terminal diversity of sansanmycin through mutasynthesis", MICROBIAL CELL FACTORIES, vol. 15, no. 1, 6 May 2016 (2016-05-06), XP055708506, DOI: 10.1186/s12934-016-0471-1
- See references of WO 2018107236A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2018107236 A1 20180621; AU 2017377671 A1 20190711; CN 110300759 A 20191001; EP 3555115 A1 20191023; EP 3555115 A4 20200805
DOCDB simple family (application)
AU 2017051394 W 20171215; AU 2017377671 A 20171215; CN 201780086783 A 20171215; EP 17881453 A 20171215